XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s Ojemdatm (Tovorafenib) for Relapsed or Refractory Braf-Altered Pediatric Low-Grade Glioma (Plgg)
随着美国食品药品管理局加快批准Day One's Ojemdatm(Tovorafenib)治疗复发或难治性Braf改性小儿低度神经胶质瘤(Plgg),XOMA实现了900万美元的里程碑